Zacks Investment Research
05 Jun 2026, 16:50 UTC · 3h ago
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Zacks Investment Research
05 Jun 2026, 16:50 UTC · 3h ago
Story key points
3 claims · impact-rated
Generic drug manufacturers are shifting investment toward biosimilars, complex generics, and specialty injectables to combat price erosion in traditional small-molecule generics. — Movement into higher-barrier-to-entry products typically leads to better margin preservation and more sustainable long-term growth.
+0.40Sandoz (SDZNY), Teva Pharmaceuticals (TEVA), and Viatris (VTRS) are identified as well-positioned to benefit from the industry's shift toward product differentiation. — Positive outlook on these specific large-cap generic players suggests potential outperformance relative to peers.
+0.30Traditional small-molecule generics are experiencing intense competition and ongoing price erosion, limiting their ability to generate profit growth. — Persistent price erosion in the core commodity generic segment acts as a headwind for companies unable to diversify their portfolios.
-0.30Ticker attribution
Continue reading
6 related stories
Top 3 movers · tap to explore
Model heads
Highlighted as a generic drugmaker well-positioned to capitalize on the industry's evolution toward complex generics and biosimilars.
Highlighted as a generic drugmaker well-positioned to capitalize on the industry's evolution toward complex generics and biosimilars.
Highlighted as a generic drugmaker well-positioned to capitalize on the industry's evolution toward complex generics and biosimilars.
[mutual] Both are highlighted as generic drugmakers operating in the same industry facing stiff competition and price erosion.
[mutual] Both are highlighted as generic drugmakers operating in the same industry facing stiff competition and price erosion.
[mutual] Both are highlighted as generic drugmakers operating in the same industry facing stiff competition and price erosion.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Zacks Investment Research
1h ago
